Bonita David P Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
14
Insider Buys Sum
$106.58M
Insider Sells Quantity
13
Insider Sells Sum
$4.19M

Insider Activity of Bonita David P

According to the SEC Form 4 filings, Bonita David P, being in a position of

  1. at Prelude Therapeutics Incorporated,
    оver the last 12 months, has bought 2815315 shares for $12.5M, and sold 0 shares,
    over all time since 2020-03-27, has bought 11989870 shares for $64.5M, and sold 0 shares.

Biography of Bonita David P

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $12,499,9991100
Sells
 $000

Comparison of Insiders on Amount of Buys and Sells

2026-04-21PurchasePrelude Therapeutics Incorporated
PRLD
2.82M
4.8551%
$4.44$12.5M-4.87%
2025-07-25PurchaseImageneBio Inc
IMA
director
83,611
3.357%
$29.90$2.5M-61.45%
2023-05-22PurchasePrelude Therapeutics Incorporated
PRLD
869,565
1.9148%
$5.75$5M-30.71%
2022-06-24PurchaseImageneBio Inc
IMA
director
162,000
1.0796%
$4.96$803,975-21.69%
2022-06-22PurchaseImageneBio Inc
IMA
director
90,225
0.4351%
$3.59$324,046+14.75%
2021-03-30PurchaseImageneBio Inc
IMA
director
423,400
9.0968%
$16.00$6.77M-49.34%
2021-01-11PurchasePrelude Therapeutics Incorporated
PRLD
83,400
–
$0$0-51.76%
2020-09-25PurchasePrelude Therapeutics Incorporated
PRLD
2.47M
56.1543%
$19.00$47M+48.63%
2020-08-21PurchasePrelude Therapeutics Incorporated
PRLD
2.07M
–
$0$0
2020-03-27PurchasePrelude Therapeutics Incorporated
PRLD
3.68M
–
$0$0
2018-10-19PurchaseSI-BONE, Inc.
SIBN
director
400,000
1.4317%
$15.00$6M-8.75%
Total: 11
*Some uncertain data for Preferred Stock share type transactions are shown in italics; for actual data please follow the link
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.